ALSO READBliss GVS Pharma provides update on its Kenyan step down subsidairy Bliss GVS Pharma advances after reporting strong Q4 numbers Bliss GVS Pharma sweetens after overseas order win Bliss GVS Pharma arm wins $111 mn contract from Kenyan firm Bliss GVS Pharma consolidated net profit rises 108.54% in the March 2017 quarter
Of Rs 0.6 per shareBliss GVS Pharma announced that the Board of Directors of the Company at its meeting held on 16 May 2017, inter alia, have recommended the final dividend of Rs 0.6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)